443.65
+2.33%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cohance Lifesciences
Its shares trade on NSE under the ticker COHANCE.NS. It has been listed since 9 March 2020. In the fiscal year to 31 March 2026, it reported revenue of ₹22.69bn and net income of ₹1.79bn. At that date it held total assets of ₹57.30bn and shareholders' equity of ₹39.11bn.
Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Mar 2020
- Employees
- 1,193
- Website
- suvenpharm.com ↗
Leadership
Pay as last reported
- Mr. Vivek SharmaExecutive Chairman of the Board, since 2024₹71.8m
- Mr. Yann D'herveChief Executive Officer
- Mr. Himanshu AgarwalChief Financial Officer₹15.6m
- Mr. Kundan JhaCompliance Officer, Company Secretary, Head- Legal
- Dr. Vetukuri Venkata Prasada RajuManaging Director, Executive Director, since 2023
- Ms. Shweta JalanNon-Executive Director
- Mr. Vinod PadikkalNon-Executive Director
- Mr. Pankaj PatwariNon-Executive Director
- Mr. Kumarapuram AnanthakrishnanNon-Executive Independent Director₹3.0m
- Ms. Matangi GowrishankarNon-Executive Independent Director₹3.0m
- Mr. Jai KrishnanNon-Executive Independent Director₹1.2m
- Mr. Udhyavara Bhadya RaoNon-Executive Independent Director₹3.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 51
- Social
- 71
- Governance
- 22
- Direct emissions (scope 1)
- 41,183 t
- Energy emissions (scope 2)
- 22,941 t
- Women in the workforce
- 5.51%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong manufacturing capabilities and infrastructure.
- Diverse and innovative product portfolio.
- Robust research and development (R&D) capabilities.
- Established global presence and strong network of distributors.
Weaknesses
- Dependence on key customers for a significant portion of revenue.
- Limited market share in certain therapeutic areas.
- Substantial competition from large pharmaceutical companies.
- Relatively low brand recognition compared to major industry players.
Opportunities
- Growing demand for generic drugs in emerging markets.
- Increasing focus on research and development for complex diseases.
- Expanding healthcare infrastructure in developing countries.
- Strategic partnerships and acquisitions to enhance product pipeline.
Threats
- Stringent regulatory requirements and compliance challenges.
- Pricing pressures from government regulations and healthcare reforms.
- Fluctuating raw material costs and supply chain disruptions.
- Potential impact of economic downturns on pharmaceutical spending.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.